Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHCOL 402 > Quiz #1 (1/6-1/8) > Flashcards

Quiz #1 (1/6-1/8) Flashcards

1
Q

Stages of synaptic transmission at the nicotinic receptor

A
  1. Depolarization of the nerve terminal by an action potential.
  2. Activation of voltage sensitive Ca2+channels in the terminal causing influx of Ca2+from extracellular medium.
  3. Fusion of synaptic vesicles with the terminal plasma membrane, causing exocytotic release of ACh.
  4. Diffusion ofACh across the synaptic cleft and binding of ACh to nicotinic ACh receptors (nAChR) in the muscle postsynaptic membrane. The distance across the synaptic cleft is small.
  5. Activation of nAChR-dependent ion channels which transiently increase the permeability of the muscle membrane to Na+and K+ions, depolarizing the endplate region. The receptor then becomes desensitized.
  6. Initiation of a muscle action potential near endplate region, which spreads through the muscle, and eventually leads to muscle contraction if the threshold is reached.
  7. Termination of synaptic transmission by hydrolysis of ACh to acetate and choline by AChE
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Somatic Neurons

A

Polysynaptic Pathway: Afferent central processes synapse onto interneurons in the ventral horn of the the spinal column.

Monosynaptic pathway: synapse directly on to motoneurons.

Renshaw cells: Inhibitory interneurons which synapse onto and inhibit motor neurons.

Axons from motor neurons synapse onto and activateskeletal muscle.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Choline Uptake and Therapeutic Target

A

Choline is brought into the nerve terminal through a Na+ dependent transporter.

Hemicholinium-3 (HC-3) inhibits uptake of choline, depleting ACh aat synapses. Not used clinically

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

ACh synthesis and therapeutic target

A

Synthesized by the enzyme choline acetyltransferase (CAT) in the cytoplasm: Choline + AcetylCoA –> ACh + CoA.

Inhibitors of CAT include choline mustard aziridinium ion and ethylcholine mustard aziridinium ion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Vesicle Fusion therapeutic target

A

Fusion is inhibited by Botulinus toxin which acts as a protease to hydrolyze SNAP-25.

Botox is used to treat dystonias (involuntary muscle spasms) including blepharospasm (eyes), wrinkle treatment, hyperhidrosis (under arm sweating), healing of anal fissures, and migraine headaches

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

NMJ Structures (4)

A

Muscle membrane: highly folded location of very dense ACh receptors.

Synaptic vesicles: across the post-synaptic muscle membrane where the acetylcholine receptors are concentrated.

Basal lamina: basement membrane structure that surrounds each muscle fiber. When there is muscle damage the basal lamina serves as a scaffold for the regenerating muscle to insure the proper orientation and imparts information concerning the specificity and “memory” of synapse formation.

Acetylcholine esterase: present on the basal lamina. Hydrolyzes ACh, and is very active.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Nicotinic receptors

A

Nicotinic receptors: ACh activated receptors at the NMJ, ligand-gated, fast response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Desensitization of nAChR

A

Continuous ACh decreases the response of ACh, this process happens in a matter of seconds and is an intrinsic property of the receptor. Conformational changes of desensitization:

Resting state (R): Channel is closed and ligand is not bound

Activated state (O): Depolarization of the membrane, channel is opened and ligand is bound

Desensitized state (D): Channel is closed but ligand remains bound

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

De-innervation Supersensitivity of nAChR

A

presence of receptors in non-synaptic regions of the muscle following muscle degeneration or de-innervation. This skeletal muscle becomes supersensitive to pharmacologic cholinergic agonists. This phenomenon stops after re-innervation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Muscarinic ACh Receptor

A

G-protein coupled receptor that acts in the ANS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Neuromuscular Blocker Therapeutic Uses

A

Endotracheal intubation, muscle relaxants during surgery, resetting of fractures, electroshock therapy to prevent physical trauma, intensive care to prevent high airway resistance and to abolish muscle rigidity, and state executions (in a cocktail of drugs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Competitive Non-Depolarizing Antagonists at nAChR Actions

A

Block muscle contractions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Competitive Non-Depolarizing Antagonists at nAChR Examples

A

Natural compounds: d-Tubocurarine (curare)

Synthetic compounds: Gallamine and pancuronium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Competitive Non-Depolarizing Antagonists at nAChR Toxic Effects

A

action at nicotinic receptor in the autonomic ganglia which can produce autonomic effects including cardiac arrhythmias and decreased blood pressure.

Curare can also cause histamine release resulting in bronchospasm,

Cardiovascular collapse: hypertension and increased BP

Respiratory paralysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Competitive Non-Depolarizing Antagonists at nAChR Overcoming Toxic Effects

A

Anti-AChE to increase ACh at synaptic cleft

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Depolarizing Partial Agonists at nAChR Actions

A

twitching, and blockade of muscle contraction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Depolarizing Partial Agonists at nAChR Examples

A

decamethazoinum-C10 and succinylcholine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Depolarizing Partial Agonists at nAChR MOA

A

bind to the receptor, activate the receptor and antagonize ACh binding. The receptor becomes desensitized due to the prolonged exposure.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Succinylcholine

A

Depolarizing Partial Agonists at nAChR. short half-life and is hydrolyzed by serum enzyme pseudo- or plasma- choline esterase. mutants for this enzyme don’t degrade succinylcholine rapidly and have prolonged apnea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Depolarizing Partial Agonists at nAChR Treating Toxic effects

A

Cannot treat with Anti-AChE because this enhances desensitization. Only treatment is artificial respiration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

AChE

A

Located in the basal lamina

Active Site: anionic site interacts with the quaternary ammonium group of ACh and the esteratic site is where ester hydrolysis occurs and contains a His and Ser

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Non-covalent and reversible AChE inhibitors

A

Example is edrophonium which interacts with the anionic site and hydrogen bonds with the histidine at the esteratic site.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Covalent and reversible AChE inhibitors

A

Examples are the carbamate esters, physostigmine and neostigmine. The covalent complex is slowly reversible (t ½ 30 minutes, effective 3-4 hours)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Covalent and irreversible AChE inhibitors

A

Examples are the organophosphates, DFP (diisoproplyflurophosphate), parathion and echothiophate. DFP is a nerve gas. Reactivation can occur with 2-PAM (pralidoxime) which forms an oxide-phosphonate. However, if the enzyme is “aged” the intermediate is extremely stable and cannot be reactivated. Aging takes 2-3 days with DFP but only 3 minutes with Soman (nerve gas)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Physiological Effects of Anti-AChE

A

Act at nAChR at the NMJ, and in sympathetic and parasympathetic ganglia.

At the NMJ this decreases the force of muscle contraction and in high doses causes receptor desensitization.

They also indirectly activate muscarinic receptors in the parasympathetic nervous systems and in sweat gland, increase GI smooth muscle motility and decrease heart rate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Myasthenia Gravis

A

autoimmune disease in which patients make Abs against their own nAChR in muscle causing neuromuscular weakness and muscular fatigue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Myasthenia Gravis Treatment

A

AChE inhibitor, neostigmine, which prolongs the time the patient can produce muscular contractions because the drug increases the lifetime and effective concentration of ACh at the neuromuscular junction.

28
Q

Atropine in Myasthenia Gravis

A

muscarinic antagonist, to suppress stimulation of ACh in the ANS

29
Q

Myasthenia Gravis Diagnosis

A

short-acting AChE inhibitor, edrophonium. Patients with Myasthenia Gravis will show a transient increase in strength lasting several minutes.

30
Q

Functions of ANS

A

Regulates the functions of the heart, blood vessels, GI tract, various types of smooth muscle and strives to maintain the internal environment against a constantly changing external environment

31
Q

ANS vs NMJ

A
  1. At the NMJ, the actions of somatic nerves are voluntary while control of the autonomic neurons is generally involuntary
  2. The target of the somatic neurons, the skeletal muscle is quiescent (not stimulated) in the absence of neuronal stimulation while the target organs of the ANS show tonic activity. E.g. your heart is always beating and you can either slow down the rate or increase the rate through the autonomic nervous system.
  3. Axons for neurons innervating skeletal muscle are found in the spinal cord. In the autonomic system, sensory information is carried by afferent pathways to the CNS where the controlling and integrating centers for the ANS are located. Efferent nerves of the ANS provide all innervated structures of the body with the exception of the skeletal muscle which is controlled by somatic neurons.
  4. ANS has presynaptic receptors to regulate the release of neurotransmitters, whereas the NMJ doesn’t
32
Q

Parasympathetic vs Sympathetic: location

A

Parasympathetic preganglion neurons originate in the midbrain, medulla and sacral portions of the spinal cord. Ganglia are closer to the target and often only innervate one effector organ.

Sympathetic preganglion neurons originate in the intermediate spinal cord. Ganglia are in the spinal cord and often innervate many effector organs

33
Q

Parasympathetic vs Sympathetic: Targets

A

Most organs are innervated by sympathetic and parasympathetic branches which often act in an antagonist manner.

34
Q

Adrenal Medulla

A

part of the sympathetic system. Contains secretory cells (chromaffin cells) that release catecholamines, e.g. epinephrine and norepinephrine in response to neuronal stimulation

35
Q

Sympathetic Effects

A

“fight or flight”
1. Heart: increased heart rate, increased contractile force

  1. Arterioles (but not skeletal muscle) and veins: vasoconstriction (increased blood pressure)
  2. Eye: dilation of pupils (mydriasis) and relaxation of ciliary muscle for far vision
  3. Lungs: dilation of bronchioles
  4. Liver: increased blood sugar (glycogen breakdown)
  5. Sweat Glands: secretion (no parasympathetic innervation)
  6. GI tract: inhibition of peristalsis and secretion
36
Q

Parasympathetic Effects

A

“rest and digest”

  1. Heart: bradycardia and reduces contractile force in the atria
  2. Eye: miosis of pupils (constriction) and contraction of ciliary muscle for near vision
  3. Lungs: Bronchial Constriction
  4. GI tract: stimulation of peristalsis and secretion

5 .Arterioles and veins (not skeletal muscle): only receive sympathetic innervation

  1. Lachrymal Glands (tear glands): secretion (no sympathetic innervation)
  2. Salivary glands: secretion (little sympathetic innervation that causes secretion)
37
Q

Synaptic Transmission through Autonomic Sympathetic Ganglia

A
  1. An initial large depolarization, EPSP, due to the activation of the ganglionic nicotinic receptor of the postganglionic neuron by ACh. Responsible for transmission through the ganglion
  2. A small hyperpolarization, slow IPSP, due to the activity of an interneuron. Serves to modulate synaptic transmission
  3. A slow or late EPSP due to activation of mAChR on the post-ganglionic neuron
38
Q

Synaptic Transmission through Parasympathetic Ganglia

A

Less is known. Studies with amphibian heart suggest the presence of a fast EPSP due to activation of nACh-R and a slow IPSP due to activation of mACh-R.

The main pathway uses ACh activating nicotinic receptors post-synaptically.

39
Q

Ganglionic Stimulating Drugs

- Nicotinic: Examples

A

Nicotine, DMPP, and TMA

40
Q

Ganglionic Stimulating Drugs - Nicotinic: MOA

A

low concentrations activate nAChR in sympathetic and parasympathetic ganglia and the adrenal medulla. High concentrations desensitize the nicotinic ACh-R in ganglionic synapses and cause blockade

41
Q

Nicotine concentration effects

A

Ganglionic stimulating drugs.

Low concentrations: sympathomimetic cardiovascular effects which include increased inotropic and chronotropic effects and parasympathetic GI effects to increase GI motility

High concentrations: convulsions

42
Q

Ganglionic Stimulating Drugs - Muscarinic

A

Examples: muscarine, pilocarpine

MOA: stimulation of sympathetic nervous system by late EPSP

Effects: direct sympathetic effects on the cardiovascular system
The experimental drug, McN-A-343, acts preferentially to stimulate mACh-R in the sympathetic ganglia and in the adrenal medulla compared to heart or vascular smooth muscle through receptor subclass specificity
43
Q

Ganglionic Blockers

Examples

A

Pentolinium, hexamethonium, and triethyl ammonium (TEA)

44
Q

Ganglionic Blockers: MOA

A

competitive antagonists that block ganglionic transmission by blocking nAChR without a change in the membrane potential of the ganglionic cells. Inhibit parasympathetic and sympathetic ganglia

45
Q

Ganglionic Blockers: Effects

A

depends on the predominant tone

Sympathetic-
Arterioles and veins: cause vasodilation
Sweat glands: anhidrois, decreases sweating

Parasympathetic-
Heart: tachycardia
Eye: mydriasis (pupillary dilation) and cycloplegia (paralysis of the intraocular muscle)
Salivary glands: Xerostomia
GI tract: relaxation of intestinal muscle, constipation
Bladder: difficulty voiding the bladder

46
Q

Ganglionic Blockers - Therapeutic uses

A

were used as hypotensive agents due to dilation of arteries and veins

47
Q

Muscarinic Synapses

A
  1. At the NM junction there is a highly specialized structure with a highly differentiated nerve terminal, there are discrete terminals; in the ANS the muscarinic receptors are more spread out to give a uniform response
  2. At the NM the synapse gap is very small 20 nm to 50 nm. At Muscarinic synapses the distance is generally larger, 20 nm to 2 µm.
  3. The response at the NM junction is very fast… less than a 100 µsec. At muscarinic synapses the response is slow, slower than 100 msec.
  4. Muscarinic receptors are coupled to GPCR whereas at the NMJ the receptors are ligand-gated ion channels
48
Q

Muscarinic Agonist classes

A

choline esters, cholinomimetic alkaloids

49
Q

Muscarinic Agonist general effect

A

mimic parasympathetic nerve stimulation

50
Q

Muscarinic Agonist, Choline Esters - Examples

A

acetylcholine, carbachol, methacholine and bethanecol

51
Q

Muscarinic Agonist, Choline Esters - MOA

A

act as agonists at mAChR

52
Q

Muscarinic Agonist, Choline Esters - Effects

A

vasodilation of vascular beds, decrease in blood pressure (NO dependent), bradycardia, bronchial constriction, pupil constriction

53
Q

Muscarinic Agonist, Choline Esters - Therapeutic Uses

A
  1. Methacholine was used in the past to control, tachycardia but not now because of side effects.
  2. Bethanechol is used as a GI tract stimulant to relieve a variety of conditions and to relieve urinary tract retention when there is no physical obstruction.
  3. ACh is used to produce brief periods of miosis during extraction of cataracts.
  4. Methacholine, bethanecol, and carbachol are used in treatment of glaucoma to cause miosis which enhances drainage of aqueous humor.
  5. Methacholine is also used for diagnosis of belladonna (a muscarinic antagonist) poisoning, and for diagnosis of bronchial hyperactivity
54
Q

Muscarinic Agonists, Cholinomimetic Alkaloids: Examples, effects, uses

A

Examples: muscarine, arecoline, pilocarpine and the synthetics oxotremorine and aceclidine

Effects: Can cross BBB and can have effects in the CNS

Therapeutic uses: pilocarpine is used for the treatment of glaucoma

Mushrooms: Amanita class mushrooms contain muscarine. Ingestion produces a number of symptoms due to over stimulation of autonomic organs, salivation, diarrhea, bradycardia and CNS effects. Atropine is used as an antidote for muscarine poisoning

55
Q

Muscarinic Antagonists

A

Belladona Alkaloids and quaternary derivatives

56
Q

Muscarinic Antagonists: Examples

A

Atropine, scopolamine, homotropine. Belladonna poisoning (night shade) is a mixture of atropine and scopolamine

57
Q

Muscarinic Antagonists: MOA

A

competitive reversible inhibition of mAChR to block parasympathetic stimulation

58
Q

Muscarinic Antagonists: Effects

A

mydriasis (pupil dilation), tachycardia (clinical dose atropine), cycloplegia, inhibit GI secretions

59
Q

Muscarinic Antagonists: quaternary derivatives

A

Do not cross the BBB and therefore have no CNS side effects

Substantial nicotinic blocking activity and can have side effects due to ganglionic and neuromuscular blockade

60
Q

Muscarinic Antagonists: Therapeutic Uses

A
  1. Preanesthetic: atropine and scopolamine reduce salivation and bronchial secretion as well as dilating bronchial passages
  2. Ophthalmology: mydriasis and cycloplegia properties. Drugs differ in duration of action and recovery time is significant (days)
  3. Peptic Ulcer: decreases motility and gastric secretion. Also inhibit intestinal tone or motility
  4. Bradycardia: Atropine. bradycardia caused by excessive stimulation of vagal tone following MI
  5. Cold and Hay Fever: Belladonna alkaloids decrease secretions
  6. Asthma: ipratropium, quaternary derivative, produces bronchodilation but does not inhibit bronchial secretions
  7. Motion sickness
61
Q

M1 receptor subtype

A

main mACh-R in sympathetic ganglia and it is preferentially activated by McN-A-343.

62
Q

M2 receptor subtype

A

main subtype in the heart and is coupled to inhibition of cAMP levels

63
Q

M3 receptor subtype

A

main subtype in smooth muscle

64
Q

M4 and M5 receptor subtype

A

are in the brain

65
Q

Muscarinic subtype MOA’s

A

M1, M3, M5 cause Ca2+ mobilization and PKC activation

M2 and M4 cause inhibition of AC through Gi

66
Q

AChE in ANS: examples, therapeutic uses

A

Terminates ACh action to produce cholinometric effects at both nicotinic and muscarinic synapses

AChE Examples: Physostigmine, neostigmine, echothiphate and organophosphates

Therapeutic Uses: glaucoma to cause miosis and increase drainage, atony of the urinary bladder by increasing GI and urinary tract motility (neostigmine) and Atropine intoxication (physostigmine).

PHCOL 402 (4 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions